Shortwave Life Sciences: 2026 Outlook for Dual-Engine Strategy

StockBox

10.8K subscribers

ShareSubscribe

Shortwave Life Sciences: 2026 Outlook for Dual-Engine Strategy In this interview, StockBox spoke to Stephen Molloy and Ron Lipsky, Executive Director and Non-Executive Director of Shortwave Life Sciences, to discuss the company’s dual-focus strategy and outlook for 2026. - Shortwave is progressing a novel treatment for anorexia nervosa, targeting a 2026 human efficacy trial - an important milestone in an area with no approved medical therapies. - The company has launched a carefully managed digital asset treasury anchored by Bitcoin and guided by regulated partners to hedge against inflation and support funding needs. - With operations in both life sciences and digital asset finance, Shortwave aims to demonstrate the strength of its dual-engine model through clinical and financial performance in 2026.